<VariationArchive VariationID="2766431" VariationName="NM_021922.3(FANCE):c.753_756dup (p.Asp253Ter)" VariationType="Duplication" Accession="VCV002766431" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-15" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2928894" VariationID="2766431">
      <GeneList>
        <Gene Symbol="FANCE" FullName="FA complementation group E" GeneID="2178" HGNC_ID="HGNC:3586" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>6p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="35452338" stop="35467102" display_start="35452338" display_stop="35467102" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="35420137" stop="35434880" display_start="35420137" display_stop="35434880" Strand="+" />
          </Location>
          <OMIM>613976</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_021922.3(FANCE):c.753_756dup (p.Asp253Ter)</Name>
      <CanonicalSPDI>NC_000006.12:35456250:TAAG:TAAGTAAG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>6p21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="35456250" stop="35456251" display_start="35456250" display_stop="35456251" variantLength="4" positionVCF="35456250" referenceAlleleVCF="T" alternateAlleleVCF="TTAAG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="35424027" stop="35424028" display_start="35424027" display_stop="35424028" variantLength="4" positionVCF="35424027" referenceAlleleVCF="T" alternateAlleleVCF="TTAAG" />
      </Location>
      <ProteinChange>D253*</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_498" sequenceAccession="LRG_498">
            <Expression>LRG_498:g.8891_8894dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.35424028_35424031dup" Assembly="GRCh37">
            <Expression>NC_000006.11:g.35424028_35424031dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.35456251_35456254dup" Assembly="GRCh38">
            <Expression>NC_000006.12:g.35456251_35456254dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011708.1" sequenceAccession="NG_011708" sequenceVersion="1" change="g.8891_8894dup">
            <Expression>NG_011708.1:g.8891_8894dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001410876.1" sequenceAccession="NM_001410876" sequenceVersion="1" change="c.753_756dup">
            <Expression>NM_001410876.1:c.753_756dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001397805.1" sequenceAccession="NP_001397805" sequenceVersion="1" change="p.Asp253Ter">
            <Expression>NP_001397805.1:p.Asp253Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_021922.3" sequenceAccession="NM_021922" sequenceVersion="3" change="c.753_756dup" MANESelect="true">
            <Expression>NM_021922.3:c.753_756dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_068741.1" sequenceAccession="NP_068741" sequenceVersion="1" change="p.Asp253Ter">
            <Expression>NP_068741.1:p.Asp253Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_498t1" sequenceAccession="LRG_498t1">
            <Expression>LRG_498t1:c.753_756dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_498p1" sequenceAccession="LRG_498p1" change="p.Asp253Terfs">
            <Expression>LRG_498p1:p.Asp253Terfs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_021922.3(FANCE):c.753_756dup (p.Asp253Ter) AND Fanconi anemia complementation group E" Accession="RCV003510293" Version="1">
        <ClassifiedConditionList TraitSetID="2393">
          <ClassifiedCondition DB="MedGen" ID="C3160739">Fanconi anemia complementation group E</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11001585</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17924555</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2393" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10471" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group E</ElementValue>
                <XRef ID="MONDO:0010953" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FANCE</ElementValue>
                <XRef Type="MIM" ID="600901" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FACE</ElementValue>
                <XRef Type="MIM" ID="600901" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">FANCE-Related Fanconi Anemia</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15324" />
                <XRef ID="15324" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3160739" DB="MedGen" />
              <XRef ID="MONDO:0010953" DB="MONDO" />
              <XRef Type="MIM" ID="600901" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8016481" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="28327120|MedGen:C3160739" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004331331" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11001585</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17924555</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asp253*) in the FANCE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCE are known to be pathogenic (PMID: 11001585, 17924555). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FANCE-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCE" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.35424027_35424028insTAAG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3160739" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8016481" TraitType="Disease" MappingType="XRef" MappingValue="C3160739" MappingRef="MedGen">
        <MedGen CUI="C3160739" Name="Fanconi anemia complementation group E" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

